Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as diclofenac diethylamine, DDEA 2.32% gel
diclofenac diethylamine, DDEA 2.32% · 1 trial · 1 indication
POM will be assessed by subject on a 100 mm Visual Analog Scale (VAS). The VAS ranges from 0 to 100 with higher score indicating higher levels of pain.
| Arm | Type | Description |
|---|---|---|
| diclofenac diethylamine, DDEA 2.32% gel | EXPERIMENTAL | diclofenac diethylamine, DDEA 2.32% gel |
| Placebo | PLACEBO_COMPARATOR | Vehicle control |
| Name | Type | Description |
|---|---|---|
| diclofenac diethylamine, DDEA 2.32% gel | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * 1\. Male or female ≥ 50 years old; 2. Symptomatic OA of one or both knees, according to ACR criteria, diagnosed at least 6 months previously; 3. Pain in either knee originates in the knee (not referred pain from other sites, such as hip or back) and no other cause of pain than...
Top 5 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 3 | PHASE3 | Eloralintide and Tirzepatide, Orforglipron, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Diclofenac diethylamine, DDEA 2.32% is a topical gel being developed for the treatment of knee osteoarthritis. It is applied to the skin over the affected joint. The asset is in Phase 3 development, and its clinical program has focused on patients with knee osteoarthritis.
Diclofenac diethylamine, DDEA 2.32% targets the enzymes PTGS2 (cyclooxygenase-2) and PTGS1 (cyclooxygenase-1). It acts as an inhibitor of these targets. This mechanism is the basis for its anti-inflammatory and analgesic activity in musculoskeletal conditions such as knee osteoarthritis.
Diclofenac diethylamine, DDEA 2.32% is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical program evaluating this topical gel formulation for knee osteoarthritis.
Diclofenac diethylamine, DDEA 2.32% is in Phase 3 development. It is an investigational product and has not been approved by the FDA. The Phase 3 trial for this asset has been completed.
Diclofenac diethylamine, DDEA 2.32% has been studied in one Phase 3 trial, NCT01967550, titled "Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)." The trial was completed, enrolled 304 patients in Germany, and was randomized, double-blind, and placebo-controlled.
Yes, diclofenac diethylamine, DDEA 2.32% and diclofenac diethylamine, DDEA 2.32% gel refer to the same product. The gel designation describes the topical formulation of this small molecule asset. Both names identify the same investigational therapy developed by Novartis for knee osteoarthritis.